Published in Hepatology on May 01, 2008
Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions. J Hepatol (2014) 1.04
Pathophysiology of portal hypertension. Clin Liver Dis (2014) 0.91
Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspects. World J Gastroenterol (2014) 0.88
Aquaporin-1 promotes angiogenesis, fibrosis, and portal hypertension through mechanisms dependent on osmotically sensitive microRNAs. Am J Pathol (2011) 0.83
Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension. J Hepatol (2014) 0.83
Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis. Eur J Clin Pharmacol (2011) 0.81
Hepatic arterial vasodilation is independent of portal hypertension in early stages of cirrhosis. PLoS One (2015) 0.77
Angiogenesis and Fibrogenesis in Chronic Liver Diseases. Cell Mol Gastroenterol Hepatol (2015) 0.76
"Non alcoholic fatty liver disease and eNOS dysfunction in humans". BMC Gastroenterol (2017) 0.75
TOR signaling in growth and metabolism. Cell (2006) 35.29
Effective targeted gene 'knockdown' in zebrafish. Nat Genet (2000) 14.40
Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol (2005) 10.65
Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol (2006) 4.71
Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci U S A (2001) 4.60
Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest (2007) 4.41
Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis. J Clin Invest (2005) 3.95
Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest (2007) 3.61
eNOS at a glance. J Cell Sci (2004) 3.14
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov (2006) 2.84
Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proc Natl Acad Sci U S A (2005) 2.81
Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J Immunol (2007) 2.64
Transforming growth factor-beta and substrate stiffness regulate portal fibroblast activation in culture. Hepatology (2007) 2.53
Distinct requirements for zebrafish angiogenesis revealed by a VEGF-A morphant. Yeast (2000) 2.53
Direct evidence for the role of caveolin-1 and caveolae in mechanotransduction and remodeling of blood vessels. J Clin Invest (2006) 2.47
Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice. Mol Cell Biol (2005) 2.25
Angiogenesis and hepatocellular carcinoma. J Hepatol (2004) 2.25
mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res (2004) 2.14
The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. Gastroenterology (2006) 2.08
Nitric oxide synthase generates nitric oxide locally to regulate compartmentalized protein S-nitrosylation and protein trafficking. Proc Natl Acad Sci U S A (2006) 1.97
The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology (2004) 1.96
Sinusoidal remodeling and angiogenesis: a new function for the liver-specific pericyte? Hepatology (2007) 1.87
A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nat Med (2005) 1.74
Rat liver sinusoidal endothelial cell phenotype is maintained by paracrine and autocrine regulation. Am J Physiol Gastrointest Liver Physiol (2004) 1.73
Hypercholesterolemia promotes P-selectin-dependent platelet-endothelial cell adhesion in postcapillary venules. Arterioscler Thromb Vasc Biol (2003) 1.73
Role of neutrophils in acute inflammatory liver injury. Liver Int (2006) 1.72
Sleeping beauty transposon-mediated gene therapy for prolonged expression. Adv Genet (2005) 1.60
Hepatocyte-specific IKK gamma/NEMO expression determines the degree of liver injury. Gastroenterology (2007) 1.57
Apoptosis of sinusoidal endothelial cells is a critical mechanism of preservation injury in rat liver transplantation. Hepatology (1998) 1.50
Expression and activation of the farnesoid X receptor in the vasculature. Proc Natl Acad Sci U S A (2004) 1.48
Age-related pseudocapillarization of the human liver. J Pathol (2003) 1.39
The third gas: H2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis. Hepatology (2005) 1.38
Syndecan-2 is essential for angiogenic sprouting during zebrafish development. Blood (2003) 1.38
The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting. Semin Cell Dev Biol (2005) 1.34
The biology of P-selectin glycoprotein ligand-1: its role as a selectin counterreceptor in leukocyte-endothelial and leukocyte-platelet interaction. Thromb Haemost (1999) 1.32
Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide. J Clin Invest (1995) 1.32
Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation (2007) 1.29
Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Hepatology (2007) 1.23
Disruption of an SP2/KLF6 repression complex by SHP is required for farnesoid X receptor-induced endothelial cell migration. J Biol Chem (2006) 1.21
Transplantation of endothelial cells corrects the phenotype in hemophilia A mice. J Thromb Haemost (2005) 1.21
Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. Am J Physiol Gastrointest Liver Physiol (2006) 1.15
Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. Circ Res (2005) 1.12
Susceptibility of murine periportal hepatocytes to hypoxia-reoxygenation: role for NO and Kupffer cell-derived oxidants. Hepatology (2004) 1.12
Hepatic targeting of transplanted liver sinusoidal endothelial cells in intact mice. Hepatology (2005) 1.11
Angiogenesis and anti-angiogenesis in hepatocellular carcinoma. Cancer Treat Rev (2006) 1.10
Cell and molecular regulation of endothelin-1 production during hepatic wound healing. Mol Biol Cell (2003) 1.05
Functional analysis of zebrafish microfibril-associated glycoprotein-1 (Magp1) in vivo reveals roles for microfibrils in vascular development and function. Blood (2006) 1.02
Phosphorylation of eNOS initiates excessive NO production in early phases of portal hypertension. Am J Physiol Heart Circ Physiol (2002) 1.00
The role of cytokines in pharmacological modulation of hepatic ischemia/reperfusion injury. Curr Pharm Des (2006) 0.98
Role of Kupffer cells in gut ischemia/reperfusion-induced hepatic microvascular dysfunction in mice. Hepatology (1997) 0.95
Regulation of postischemic liver injury following different durations of ischemia. Am J Physiol Gastrointest Liver Physiol (2002) 0.95
Heme oxygenase attenuates oxidative stress and inflammation, and increases VEGF expression in portal hypertensive rats. J Hepatol (2005) 0.95
Reduced inflammatory response and increased microcirculatory disturbances during hepatic ischemia-reperfusion injury in steatotic livers of ob/ob mice. Am J Physiol Gastrointest Liver Physiol (2007) 0.94
Mesenteric vasoconstriction triggers nitric oxide overproduction in the superior mesenteric artery of portal hypertensive rats. Gastroenterology (2003) 0.93
NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats. Gut (2006) 0.93
Role of platelets in hypercholesterolemia-induced leukocyte recruitment and arteriolar dysfunction. Microcirculation (2006) 0.92
Nitric oxide biology and the liver: report of an AASLD research workshop. Hepatology (2004) 0.91
The future of GI and liver research: editorial perspectives: II. Modulating leukocyte recruitment to splanchnic organs to reduce inflammation. Am J Physiol Gastrointest Liver Physiol (2003) 0.90
LPS inhibits endothelin-1-induced endothelial NOS activation in hepatic sinusoidal cells through a negative feedback involving caveolin-1. Hepatology (2006) 0.89
Hypercholesterolemia promotes leukocyte-dependent platelet adhesion in murine postcapillary venules. Microcirculation (2004) 0.85
FK409, a new nitric-oxide donor, suppresses smooth muscle proliferation in the rat model of balloon angioplasty. Atherosclerosis (1995) 0.85
Mediators of CD18/P-selectin-dependent constriction of venule-paired arterioles in hypercholesterolemia. Microvasc Res (2006) 0.84
Today's hepatic stellate cells: not your father's sternzellen. Hepatology (2007) 0.82
Chemokine-mediated angiogenesis: an essential link in the evolution of airway fibrosis? J Clin Invest (2005) 0.82
Remote trauma sensitizes hepatic microcirculation to endothelin via caveolin inhibition of eNOS activity. Shock (2004) 0.78
The Budd-Chiari syndrome. N Engl J Med (2004) 3.95
MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology (2005) 2.99
Correlation of magnetic resonance imaging tumor volume with histopathology. J Urol (2012) 2.55
Diverse origin and function of cells with endothelial phenotype obtained from adult human blood. Circ Res (2003) 2.50
11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nucl Med (2012) 2.42
Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology (2013) 2.35
A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol (2004) 1.83
Nitric oxide promotes endothelial cell survival signaling through S-nitrosylation and activation of dynamin-2. J Cell Sci (2007) 1.66
Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver disease. Gastroenterology (2010) 1.60
Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function. Gastroenterology (2008) 1.40
The third gas: H2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis. Hepatology (2005) 1.38
Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension? J Hepatol (2010) 1.37
Regulatory role of dynamin-2 in VEGFR-2/KDR-mediated endothelial signaling. FASEB J (2005) 1.37
Use of patient-specific MRI-based prostate mold for validation of multiparametric MRI in localization of prostate cancer. Urology (2012) 1.28
Comparison of endorectal coil and nonendorectal coil T2W and diffusion-weighted MRI at 3 Tesla for localizing prostate cancer: correlation with whole-mount histopathology. J Magn Reson Imaging (2013) 1.27
Mechanisms of nitric oxide interplay with Rho GTPase family members in modulation of actin membrane dynamics in pericytes and fibroblasts. Am J Pathol (2005) 1.22
Myoferlin regulates vascular endothelial growth factor receptor-2 stability and function. J Biol Chem (2007) 1.19
Reduced nicotinamide adenine dinucleotide phosphate oxidase 2 plays a key role in stellate cell activation and liver fibrogenesis in vivo. Gastroenterology (2010) 1.18
Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. Hepatology (2011) 1.17
KLF11-mediated repression antagonizes Sp1/sterol-responsive element-binding protein-induced transcriptional activation of caveolin-1 in response to cholesterol signaling. J Biol Chem (2004) 1.12
Pancreatic stellate cell models for transcriptional studies of desmoplasia-associated genes. Pancreatology (2010) 1.11
Characterization of the CXCR4 signaling in pancreatic cancer cells. Int J Gastrointest Cancer (2006) 1.11
Inhibition of GTP-dependent vesicle trafficking impairs internalization of plasmalemmal eNOS and cellular nitric oxide production. J Cell Sci (2003) 1.02
The proline-rich domain of dynamin-2 is responsible for dynamin-dependent in vitro potentiation of endothelial nitric-oxide synthase activity via selective effects on reductase domain function. J Biol Chem (2002) 0.99
Designing nanoconjugates to effectively target pancreatic cancer cells in vitro and in vivo. PLoS One (2011) 0.96
The methionine connection: homocysteine and hydrogen sulfide exert opposite effects on hepatic microcirculation in rats. Hepatology (2008) 0.96
Focal adhesion assembly in myofibroblasts fosters a microenvironment that promotes tumor growth. Am J Pathol (2010) 0.95
Nitric oxide biology and the liver: report of an AASLD research workshop. Hepatology (2004) 0.91
Interplay of tumor microenvironment cell types with parenchymal cells in pancreatic cancer development and therapeutic implications. J Gastrointest Cancer (2009) 0.90
Therapeutic administration of nitric oxide synthase inhibitors reverses hyperalgesia but not inflammation in a rat model of polyarthritis. Pain (2002) 0.87
Signaling lymphocyte activation molecule regulates development of colitis in mice. Gastroenterology (2012) 0.84
Documenting the location of systematic transrectal ultrasound-guided prostate biopsies: correlation with multi-parametric MRI. Cancer Imaging (2011) 0.83
Modeling our way toward the optimal management of variceal hemorrhage. Am J Gastroenterol (2004) 0.78
New insights into the pathobiology of portal hypertension. Hepatol Res (2009) 0.78
Centrilobular necrosis after orthotopic liver transplantation: association with acute cellular rejection and impact on outcome. Liver Transpl (2004) 0.77
Activated human hepatic stellate cells promote growth of human hepatocellular carcinoma in a subcutaneous xenograft nude mouse model. Cell Biochem Biophys (2014) 0.77
Splenectomy attenuates streptococcal cell wall-induced arthritis and alters leukocyte activation. Arthritis Rheum (2003) 0.77
Therapy for portal hypertension: What is our pipeline? Hepatology (2009) 0.76
Does nadolol improve the efficacy of endoscopic variceal ligation in the treatment of variceal bleeding? Nat Clin Pract Gastroenterol Hepatol (2005) 0.75
GRK2 makes trouble: a no-NO in portal hypertension. Gastroenterology (2006) 0.75